ImmunoCellular Therapeutics

ImmunoCellular Therapeutics, Ltd. is a Los Angeles-based clinical stage company developing immune-based therapies for the treatment of brain and other cancers. ImmunoCellular is conducting a Phase II trial of its lead product candidate, ICT-107, a dendritic cell-based vaccine targeting multiple tumor-associated antigens for glioblastoma. ImmunoCellularís pipeline also includes ICT-121, a dendritic cell vaccine targeting CD133, as well as ICT-140, a dendritic cell vaccine targeting ovarian cancer antigens and cancer stem cells.